Effect of intramuscular 15-methyl prostaglandin F(2α) after second- trimester delivery

Obstetrics and Gynecology

Volumn 89, Issue 1, 1997, Pages 5-9

  Carlan, S J ^a   Gushwa, J P ^b   O'Brien, W F ^b   Vu, Thao ^b  

^a ORLANDO HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPROST; HEMOGLOBIN; MISOPROSTOL; OXYTOCIN; PROSTAGLANDIN E2;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CURETTAGE; DOUBLE BLIND PROCEDURE; FEMALE; FETUS DEATH; FETUS MALFORMATION; GESTATIONAL AGE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LABOR; MATERNAL DISEASE; PLACENTA; PREGNANCY TERMINATION; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION;

DINOPROST; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; OXYTOCICS; PREGNANCY; PREGNANCY TRIMESTER, SECOND;

EID: 0031031533     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(96)00433-4     Document Type: Article

References (13)

1. Kirz DS, Haag MK. Management of the third stage of labor in pregnancies terminated by prostaglandin E2. Am J Obstet Gynecol 1989;160:412-4.
2. Combs CA, Laros RK. Prolonged third stage of labor: Morbidity and risk factors. Obstet Gynecol 1991;77:863-7.
3. Castadot RG. Pregnancy termination: Techniques, risks, and complications and their management. Fertil Steril 1986;45:5-17.
4. Schenker JR, Margalioth EJ. Intrauterine adhesions: An updated appraisal. Fertil Steril 1982;37:593-610.
5. American College of Obstetricians and Gynecologists. Methods of midtrimester abortion. ACOG technical bulletin no. 109. Washington, DC: American College of Obstetricians and Gynecologists, 1987.
6. Anjaneyulu R, Devi PK, Jain S, Kanthamani CR, Vijaya R, Raghavan KS. Prophylactic use of 15(S) 15 methyl PGF 2 alpha by intramuscular route - controlled clinical trial. Acta Obstet Gynecol Scand Suppl 1988;145:9-11.
7. Winkler CL, Gray SE, Hauth JC, Owen J, Tucker JM. Mid-second-trimester labor induction: Concentrated oxytocin compared with prostaglandin E2 vaginal suppositories. Obstet Gynecol 1991;77: 297-300.
8. Rayburn W, Laferla J. Second trimester pregnancy termination for genetic abnormalities. J Reprod Med 1982;27:584-7.
9. Castadot R. Pregnancy termination: Technique, risks, and complications and their management. Fertil Steril 1986;45:5-9.
10. Romero R, Hsu YC, Athanassiadis AP, Hagay Z, Avila C, Nores J, et al. Preterm delivery: A risk factor for retained placenta. Am J Obstet Gynecol 1990;163:823-5.
11. Chou MM, MacKenzie IZ. A prospective, double-blind, randomized comparison of prophylactic intramyometrial 15-methyl prostaglandin F2 alpha, 125 micrograms, and intravenous oxytocin, 20 units, for the control of blood loss at elective cesarean section. Am J Obstet Gynecol 1994;171:1356-60.
12. Rall TW. Drugs affecting uterine motility; oxytocin, prostaglandin, ergot alkaloids, and other drugs; tocolytic agents. In: Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman: The pharmacological basis of therapeutics. 8th ed. New York: Macmillan, 1990:933-48.
13. Kerekes L, Domokos N. The effect of prostaglandin F2 alpha on third stage of labour. Prostaglandins 1979;18:161-6.